BIODESIX INC (BDSX)
US09075X1081 - Common Stock
We assign a fundamental rating of 3 out of 10 to BDSX. BDSX was compared to 113 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. BDSX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BDSX had negative earnings in the past year.
BDSX had a negative operating cash flow in the past year.
In the past 5 years BDSX always reported negative net income.
BDSX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -42.65%, BDSX is doing worse than 84.96% of the companies in the same industry.
BDSX's Return On Equity of -157.30% is on the low side compared to the rest of the industry. BDSX is outperformed by 80.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.65% | ||
| ROE | -157.3% | ||
| ROIC | N/A |
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 77.72%, BDSX belongs to the best of the industry, outperforming 92.92% of the companies in the same industry.
BDSX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
2. Health
2.1 Basic Checks
BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BDSX has been increased compared to 1 year ago.
Compared to 5 years ago, BDSX has more shares outstanding
BDSX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.91, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.91, BDSX is not doing good in the industry: 85.84% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.30 is on the high side and indicates that BDSX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.30, BDSX is not doing good in the industry: 69.03% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.3 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.91 |
ROIC/WACCN/A
WACC9.26%
2.3 Liquidity
A Current Ratio of 3.40 indicates that BDSX has no problem at all paying its short term obligations.
BDSX's Current ratio of 3.40 is amongst the best of the industry. BDSX outperforms 91.15% of its industry peers.
BDSX has a Quick Ratio of 3.40. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.40, BDSX belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.4 | ||
| Quick Ratio | 3.4 |
3. Growth
3.1 Past
BDSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.67%, which is quite impressive.
The Revenue has grown by 48.90% in the past year. This is a very strong growth!
Measured over the past years, BDSX shows a quite strong growth in Revenue. The Revenue has been growing by 19.16% on average per year.
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.54%
3.2 Future
The Earnings Per Share is expected to grow by 20.84% on average over the next years. This is a very strong growth
BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.31% yearly.
EPS Next Y45.34%
EPS Next 2Y28.84%
EPS Next 3Y20.84%
EPS Next 5YN/A
Revenue Next Year41.14%
Revenue Next 2Y35.68%
Revenue Next 3Y31.31%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BDSX's earnings are expected to grow with 20.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.84%
EPS Next 3Y20.84%
5. Dividend
5.1 Amount
No dividends for BDSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODESIX INC
NASDAQ:BDSX (11/21/2024, 8:14:32 PM)
After market: 1.24 +0.04 (+3.33%)1.2
+0.01 (+0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap174.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.65% | ||
| ROE | -157.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.3 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.4 | ||
| Quick Ratio | 3.4 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y45.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y